Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Abboud

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|December 9, 2015
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive EventsMatthew M Heeney, Carolyn C Hoppe, Miguel R Abboud, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 30, 2020
Pathobiologic Mechanisms of Neurodegeneration in Osteopetrosis Derived From Structural and Functional Analysis of 14 ClC-7 MutantsEleonora Di Zanni, Eleonora Palagano, Laura Lagostena, et al.
American Journal of Hematology|December 2, 2020
Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)Ifeyinwa Osunkwo, Biree Andemariam, Caterina P Minniti, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
The New England Journal of Medicine|June 15, 2019
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseElliott Vichinsky, Carolyn C Hoppe, Kenneth I Ataga, et al.
Blood|September 2, 2009
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injuryThomas V Adamkiewicz, Miguel R Abboud, Carole Paley, et al.
Nature Genetics|April 4, 2017
Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytesMaximilian Witzel, Daniel Petersheim, Yanxin Fan, et al.
Journal of Oncology Practice|July 12, 2017
Renal Medullary Carcinoma: Establishing Standards in PracticeKathryn E Beckermann, Deva Sharma, Shruti Chaturvedi, et al.
Science Translational Medicine|March 14, 2014
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicityChristian Jörg Braun, Kaan Boztug, Anna Paruzynski, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|December 9, 2015
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive EventsMatthew M Heeney, Carolyn C Hoppe, Miguel R Abboud, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 30, 2020
Pathobiologic Mechanisms of Neurodegeneration in Osteopetrosis Derived From Structural and Functional Analysis of 14 ClC-7 MutantsEleonora Di Zanni, Eleonora Palagano, Laura Lagostena, et al.
American Journal of Hematology|December 2, 2020
Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)Ifeyinwa Osunkwo, Biree Andemariam, Caterina P Minniti, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
The New England Journal of Medicine|June 15, 2019
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseElliott Vichinsky, Carolyn C Hoppe, Kenneth I Ataga, et al.
Blood|September 2, 2009
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injuryThomas V Adamkiewicz, Miguel R Abboud, Carole Paley, et al.
Nature Genetics|April 4, 2017
Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytesMaximilian Witzel, Daniel Petersheim, Yanxin Fan, et al.
Journal of Oncology Practice|July 12, 2017
Renal Medullary Carcinoma: Establishing Standards in PracticeKathryn E Beckermann, Deva Sharma, Shruti Chaturvedi, et al.
Science Translational Medicine|March 14, 2014
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicityChristian Jörg Braun, Kaan Boztug, Anna Paruzynski, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 16